OINDPnews


Copley Scientific banner

Medical

Study finds that CF patients would give up 5+ years of their lives to use a DPI instead of a standard nebulizer

A study published online in the American Journal of Pharmaceutical Benefits on August 20, 2015 found that approximately 90% of adult cystic fibrosis patients surveyed preferred using a dry powder inhaler to using a standard nebulizer if the cost is the same. On average, the patients said that they would be willing to give up 5.3 years of life, out of an expected 40 … [Read more...] about Study finds that CF patients would give up 5+ years of their lives to use a DPI instead of a standard nebulizer

Phase 3 data show Stiolto/Spiolto Respimat improves quality of life

Boehringer Ingelheim has published new data from the two OTEMTO Phase 3b trials of the Stiolto/Spiolto Respimat tiotropium/olodaterol SMI for the treatment of COPD. The data show that the inhaler produced clinically meaningful improvements in quality of life versus placebo as measured by the St. George's Respiratory Questionnaire (SRGQ). The soft mist inhaler is … [Read more...] about Phase 3 data show Stiolto/Spiolto Respimat improves quality of life

Pulmatrix announces plans for Phase 1 trial of inhaled anti-fungal for CF, BE study for LAMA

According to an update from Pulmatrix, the company has enough capital to fund development of its inhaled drug portfolio through the middle of 2017, and its plans over the next year and a half include the initiation of a Phase 1 trial of PUR1900 for the treatment of cystic fibrosis, and a pharmacokinetic bioequivalence study of PUR0200 for the treatment of COPD. … [Read more...] about Pulmatrix announces plans for Phase 1 trial of inhaled anti-fungal for CF, BE study for LAMA

OptiNose reports positive results from Phase 1 trial of intranasal oxytocin for autism

OptiNose has announced that a study comparing OPN-300 intranasal oxytocin to intravenous oxytocin for the treatment of autism showed the achievement of similar blood levels but significantly greater social-cognitive effects after intranasal administration. The results were published online July 14, 2015 in Translational Psychiatry. The randomized, … [Read more...] about OptiNose reports positive results from Phase 1 trial of intranasal oxytocin for autism

Inhaled Ebola vaccine shows promise

A study published July 13, 2015 in the Journal of Clinical investigation demonstrated that an inhaled vaccine created by a team from The University of Texas Medical Branch at Galveston (UTMB) and the National Institutes of Health protected primates against the Ebola virus. The vaccine was aerosolized using a nebulizer and delivered through a mask to a group of … [Read more...] about Inhaled Ebola vaccine shows promise

BMJ article argues that GOLD criteria lead to signficant misdiagnosis of COPD and overprescription of inhaled therapies

According to the authors of an article published in The BMJ on July 1, 2015, the Global Initiative for Obstructive Lung Disease (GOLD) criteria for COPD diagnosis result in significant overdiagnosis and overprescription of inhalers, especially in older men, and should be modified. Martin Miller of the University of Birmingham and Mark Levy of the Harrow Clinical … [Read more...] about BMJ article argues that GOLD criteria lead to signficant misdiagnosis of COPD and overprescription of inhaled therapies

Study finds that discontinuing ICS reduces risk of pneumonia in COPD patients

A study published online in CHEST on June 25, 2015 finds that discontinuing inhaled corticosteroids for COPD patients reduced the risk of pneumonia by 37%, with the greatest reduction in risk associated with stopping inhaled fluticasone. The reduction in risk was not as great after discontinuation of budesonide. The study authors identified over 103,000 COPD … [Read more...] about Study finds that discontinuing ICS reduces risk of pneumonia in COPD patients

OptiNose announces positive results from Phase 3 trial of intranasal fluticasone for nasal polyps

OptiNose has announced positive results from the 24-week Phase 3 trial of OPN-375, an intranasal fluticasone product for the treatment for nasal polyps based on the company's Bi-Directional Breath-Powered delivery system. The study showed statistically significant reduction in the primary endpoints, nasal congestion/obstruction symptoms as reported by patients and in … [Read more...] about OptiNose announces positive results from Phase 3 trial of intranasal fluticasone for nasal polyps

AmpliPhi study demonstrates viability of bacteriophages after nebulization

AmpliPhi BioSciences has announced that a study performed in conjunction with the Royal Brompton Hospital and Imperial College, UK showed that a variety of bacteriophages remain viable against P. aeruginosa after nebulization. Three different commercially available nebulizers were used to test four different bacteriophages. Earlier this year, AmpliPhi announced … [Read more...] about AmpliPhi study demonstrates viability of bacteriophages after nebulization